For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Rubius Therapeutics, Inc.

USPTO Granted Patents = 16

% Expired Patents = 56.3

EPO Patents = 3

Trademarks = 6

Forward Citations = 122

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Jordi Mata-Fink (15 out of 26 patents)

Avak Kahvejian (14 out of 32 patents)

John Round (14 out of 14 patents)

4. Noubar Boghos Afeyan (14 out of 77 patents)

5. David Arthur Berry (7 out of 87 patents)

6. Sivan Elloul (6 out of 6 patents)

7. Tom Wickham (5 out of 5 patents)

8. Tiffany F Chen (5 out of 5 patents)

9. Robert J Deans (4 out of 17 patents)

10. Torben Straight Nissen (4 out of 4 patents)

11. Nathan Dowden (4 out of 4 patents)

12. Lenka Hoffman (1 out of 4 patents)

13. Thomas Joseph Wickham (1 out of 15 patents)

14. Xuqing Zhang (1 out of 1 patent)

15. Carolyn Sayre (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 11576934 - Methods and compositions for immunomodulation (2023-02-14),

2. 11554141 - Methods and compositions for immunomodulation (2023-01-17),

3. 11141433 - Therapeutic cell systems and methods for treating cancer and infectious diseases (2021-10-12),

4. 11020435 - Functionalized erythroid cells (2021-06-01),

5. 10869898 - Methods and compositions for immunomodulation (2020-12-22),

6. 10716811 - Compositions and methods related to multimodal therapeutic cancer indications (2020-07-21),

7. 10568910 - Compositions and methods related to engineered erythroid cells comprising IL-15 (2020-02-25),

8. 10557119 - Erythroid cells comprising phenylalanine ammonia lyase (2020-02-11),

9. 10517897 - Methods related to engineered erythoid cells comprising 4-1BBL (2019-12-31),

10. 10456421 - Compositions and methods related to engineered erythoid cells comprising 4-1BBL (2019-10-29),

11. 10344263 - Synthetic membrane-receiver complexes (2019-07-09),

12. 10329531 - Synthetic membrane-receiver complexes (2019-06-25),

13. 10301594 - Synthetic membrane-receiver complexes (2019-05-28),

14. 10301593 - Synthetic membrane-receiver complexes (2019-05-28),

15. 10253296 - Synthetic membrane-receiver complexes (2019-04-09),

Rubius Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of red cell therapeutics. The company focuses on harnessing the unique properties of red blood cells to create innovative therapies for various diseases, including cancer and autoimmune disorders. Rubius aims to transform the treatment landscape through its proprietary technology platform, which enables the engineering of red blood cells to deliver therapeutic agents effectively and safely. Their research emphasizes advancing cell-based therapies to improve patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Rubius Therapeutics, Inc.

16 Patents

#164 in Cambridge, MA

#1,202 in Massachusetts

#19,898 in US

#37,766 in the World

Cambridge, MA, United States of America

Rubius Therapeutics, Inc.

Forward Citations = 122

18 inventors:

Jordi Mata-Fink (15 out of 26 patents)

Avak Kahvejian (14 out of 32 patents)

John Round (14 out of 14 patents)

4. Noubar Boghos Afeyan (14 out of 77 patents)

5. David Arthur Berry (7 out of 87 patents)

Please report any incorrect information to [email protected]

Loading…